A 52-year-old woman with a 30-year history of chronic gastroesophageal reflux disease (GERD) undergoes upper endoscopy for persistent dysphagia. Endoscopy reveals a salmon-pink segment in the distal esophagus replacing the normal pale squamous mucosa. Biopsy shows columnar epithelium with goblet cells (intestinal-type mucosa) in the esophagus. The patient has no dysphagia at present and endoscopic surveillance is planned. Six months later, repeat biopsy from the same site shows columnar epithelium with goblet cells, but now with focal areas of nuclear enlargement, increased mitotic figures, and loss of normal glandular architecture. What is the most appropriate pathological interpretation of the change that has occurred?

Explanation

## Pathological Progression: Metaplasia → Dysplasia **Key Point:** The patient has progressed from Barrett esophagus (metaplasia) to dysplasia. This represents a critical step in the adenocarcinoma sequence and significantly increases the risk of malignant transformation. ## Barrett Esophagus: Definition and Progression Barrett esophagus is a complication of chronic GERD in which the normal stratified squamous epithelium of the distal esophagus is replaced by metaplastic columnar epithelium with intestinal differentiation (goblet cells). This is a **reversible adaptive response** to chronic acid reflux injury. ## The Dysplasia Spectrum in Barrett Esophagus | Stage | Histology | Features | Malignant Risk | Management | |-------|-----------|----------|----------------|------------| | **Non-dysplastic Barrett** | Columnar epithelium with goblet cells; normal architecture | No atypia; normal mitoses | ~0.2–0.5% per year | PPI therapy, surveillance q 2–3 years | | **Low-grade dysplasia (LGD)** | Columnar epithelium; mild nuclear enlargement and hyperchromasia | Increased mitoses; preserved architecture | ~5% per year | PPI therapy, repeat endoscopy in 3–6 months | | **High-grade dysplasia (HGD)** | Marked nuclear atypia, hyperchromasia, disorganized architecture | Loss of glandular organization; frequent mitoses | ~30% per year | Endoscopic therapy (RFA, EMR) or esophagectomy | | **Adenocarcinoma** | Invasion through basement membrane | Malignant cells in submucosa or deeper | Already invasive | Surgical resection ± chemotherapy | **Clinical Pearl:** The salmon-pink appearance on endoscopy is due to the columnar epithelium being more vascular and less keratinized than normal squamous epithelium. This color change is a visual clue to Barrett metaplasia. **High-Yield:** The critical finding in the repeat biopsy is the appearance of **nuclear enlargement, increased mitotic figures, and loss of normal glandular architecture** — these are hallmarks of dysplasia. This represents progression along the adenocarcinoma sequence (GERD → Barrett metaplasia → dysplasia → adenocarcinoma). **Mnemonic:** **BAD** — Barrett esophagus → Atypia (dysplasia) → Degeneration (adenocarcinoma). ## Clinical Significance of Dysplasia 1. **Increased Malignant Potential:** Dysplasia is a precancerous lesion. The presence of atypia indicates that carcinogenic changes are accumulating in the epithelium. 2. **Surveillance and Intervention:** High-grade dysplasia requires aggressive management (endoscopic ablation or esophagectomy). Low-grade dysplasia requires close surveillance and repeat endoscopy within 3–6 months. 3. **Irreversibility:** Unlike metaplasia, dysplasia does not regress with acid suppression alone. ```mermaid flowchart TD A[Chronic GERD]:::action --> B[Squamous epithelium injury]:::outcome B --> C[Metaplasia: Columnar epithelium with goblet cells]:::outcome C --> D{Further carcinogenic hits?}:::decision D -->|No| E[Non-dysplastic Barrett<br/>Surveillance q2-3 years]:::action D -->|Yes| F[Low-grade dysplasia<br/>Repeat EGD in 3-6 months]:::action F --> G{Dysplasia persists?}:::decision G -->|Yes| H[High-grade dysplasia<br/>Endoscopic ablation or esophagectomy]:::urgent G -->|No| E H --> I[Adenocarcinoma]:::urgent ``` [cite:Robbins 10e Ch 17]